Investigating Patient Satisfaction With Oral Anti-Cancer Treatment

NCT02247583

Last updated date
Study Location
Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie
Leuven, , 3000, Belgium
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Clear Cell Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who are 18 years or older, and who can be contacted by phone and/or e-mail are eligible for the study

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients who are not able to understand Dutch or French will be excluded from the
study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Clear Cell Renal Cell CarcinomaBiomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib
NCT03592199
  1. São Paulo,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Clear Cell Renal Cell CarcinomaInvestigating Patient Satisfaction With Oral Anti-Cancer Treatment
NCT02247583
  1. Leuven,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Investigating Patient Satisfaction With Oral Anti-Cancer Treatment
Official Title Investigating Patient Satisfaction With Oral Anti-Cancer Treatment. Prospective Non-interventional Non-controlled Multicenter Observational Study to Evaluate Aspects of Pharmaceutical Care in Patients With Advanced Renal Cell Carcinoma Treated With an Oral Anti-cancer Drug.
Brief Summary

Prospective non-interventional non-controlled multicenter observational study to evaluate aspects of pharmaceutical care in patients with advanced renal cell carcinoma treated with an oral anti-cancer drug.

The main objective of this study is to evaluate the patient perspective in the treatment of advanced renal cell carcinoma with an oral anti-cancer drug.

The following aspects will be investigated:

  • Intrinsic desire for information about treatment.
  • Patient satisfaction with treatment information.
  • Patient satisfaction with treatment.
  • Medication adherence.
  • Health-related quality of life.
  • The role of different health care professionals in the treatment of RCC with oral drugs

This study should reveal information necessary for the development of pharmacotherapeutic care concepts that meet the needs of cancer patients treated with an oral anti-cancer drug over a long period.

Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population mRCC patients starting with an oral anti-cancer treatment
Condition Clear Cell Renal Cell Carcinoma
Intervention Not Provided
Study Groups/Cohorts mRCC patients
Patients with metastatic renal cell carcinoma
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: September 19, 2014)
90
Original Actual Enrollment Same as current
Actual Study Completion Date July 2013
Actual Primary Completion Date July 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients who are 18 years or older, and who can be contacted by phone and/or e-mail are eligible for the study

Exclusion Criteria:

  • Patients who are not able to understand Dutch or French will be excluded from the study
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Belgium
Removed Location Countries  
 
Administrative Information
NCT Number NCT02247583
Other Study ID Numbers VF/2010/03
s52586 ( Registry Identifier: Clinical Trial Center UZ Leuven )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Sandra De Coster, KU Leuven
Study Sponsor KU Leuven
Collaborators
  • Flemish League Against Cancer
  • Pfizer
  • Novartis
  • GlaxoSmithKline
Investigators
Study Director:Veerle Foulon, ProfessorKatholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie
PRS Account KU Leuven
Verification Date September 2014